Same-visit STI screening for FQHC budgets and FQHC patients.
Wholesale pricing scoped to HRSA grant budgets, single-visit workflow that survives the transportation barriers FQHC patients face, and reporting compatibility with HEDIS and UDS.
Loss-to-follow-up is the program metric.
FQHCs and look-alikes serve patient populations where transportation, work schedules, and housing instability make the second visit a real obstacle. If a positive screening result arrives after the patient is gone, the program loses both the patient outcome and the HEDIS/UDS completion line.
- 01 Patients face transportation, scheduling, and follow-up barriers that make second-visit return rates structurally lower than other settings.
- 02 340B and HRSA grant budgets demand a low and predictable cost-per-result; per-CPT send-out unpredictability erodes program economics.
- 03 Loss-to-follow-up on positive screening results is one of the most-watched UDS metrics — and one of the hardest to move without a workflow change.
- 04 Mobile, outreach, and Title X clinics often operate outside a fixed lab-courier loop, making send-out NAAT logistically painful.
A wholesale price built around grant budgets.
UroSure is priced and configured for the FQHC/HRSA buyer. Wholesale tiers fit Title X and Section 330 budgets. The single-visit workflow keeps screening completion inside one encounter, which supports the HEDIS and UDS lines most program managers care about.
Fit
- Same-visit result closes the screening loop in one encounter, removing the follow-up step that drives FQHC loss-to-follow-up metrics.
- Wholesale per-kit pricing fits HRSA grant and Title X budgets with Net-30/Net-60 invoicing available on approved credit.
- Single-specimen workflow extends naturally to mobile and outreach clinics where multi-specimen NAAT logistics break down.
- Supports HEDIS and UDS reporting on STI-screening completion by capturing the result inside the encounter that initiated screening.
Use cases
- Annual STI screening for sexually active patients during regular primary-care visits.
- Title X family-planning encounters where same-visit screening is a program objective.
- Mobile and outreach clinics serving rural, migrant, or unhoused populations.
- Look-alike sites under HRSA Section 330 needing predictable per-test costs.
Economics
- Net-30 and Net-60 invoicing available for grant-funded buyers on approved credit.
- Volume tier pricing at 1, 5, 25, and 100+ cases for multi-site networks.
- 340B Drug Pricing Program qualification — TBD: client confirms eligibility.
- Compatible with the funding sources listed on the Solutions Hub (Title X, Ryan White Part C, CDC PS21-2102, SAMHSA, state/county contracts).
FQHCs and Community Health Centers, in detail.
01 Does UroSure qualify for 340B drug pricing?
02 Is wholesale pricing compatible with Title X budgets?
03 Can UroSure be deployed in mobile and outreach clinics?
04 How does this map to HEDIS and UDS reporting?
05 What's the procurement workflow for federal and state buyers?
Bring UroSure to your practice.
Order a paid five-pack sample, or request a wholesale pricing quote sized for your practice.